Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.
|Videos|March 12, 2011
Laura Metcalfe on Colorectal Screening
Author(s)Laura Metcalfe, MSN, RN
Laura Metcalfe, MSN, RN, APN, C, AOCNS Advanced Practice Nurse, GI Division from John Theurer Cancer Center on Colorectal Screening
Advertisement
Laura Metcalfe, MSN, RN, APN, C, AOCNS Advanced Practice Nurse, GI Division from John Theurer Cancer Center on Colorectal Screening
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Lirafugratinib was added as a category 2A subsequent-line option for cholangiocarcinoma with an FGFR2 fusion or rearrangement and disease progression.
Dana-Farber, Mass General Brigham, and Broad Institute researchers uncovered clues to why colorectal cancer can be more aggressive in younger people.
First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
Fox Chase researchers identified ANO6 as a potential pancreatic cancer target; blocking it slowed tumor growth and reduced immune suppression in preclinical studies.
Breakthroughs with daraxonrasib in pancreatic cancer pave the way for continued investment in understanding the fundamental biology of cancers.
Advertisement
Advertisement
Trending on OncLive
1
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
2
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
3
FDA Approves Pimicotinib for Symptomatic TGCT
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5